{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-033856","form_type":"8-K","ticker":"IRD","cik":"0001228627","company_name":"Opus Genetics, Inc.","filed_at":"2026-05-12T11:01:41+00:00","discovered_at":"2026-05-12T11:05:00.252128+00:00","generated_at":"2026-05-12T11:08:45.874030+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Opus Genetics Q1 net loss $65.5M; cash $60M; enters $35M Oberland debt facility","bullets":["Net loss $65.5M ($0.75 per share) vs $8.2M loss a year ago; includes non-cash warrant liability fair value change.","Revenue $2.2M from Viatris collaboration, down from $4.4M.","Cash $60M at March 31; post-quarter $35M senior secured notes from Oberland Capital plus $5M equity; total ~$90M funds into 2029.","LCA5 program accepted into FDA's RDEP program; pivotal Phase 3 enrollment ongoing, dosing expected Q4 2026.","BEST1 Cohort 1 topline data expected September 2026; R&D Science Forum June 16."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-033856","json":"https://secwatch.observer/filing/0001628280-26-033856.json","markdown":"https://secwatch.observer/filing/0001628280-26-033856.md","text":"https://secwatch.observer/filing/0001628280-26-033856.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1228627/000162828026033856/0001628280-26-033856-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1228627/000162828026033856/ird-20260512.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-12T11:08:45.874030+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9998ba44efabe7d00994c397fe5d7ed5e4ad0f45","claim":"Opus Genetics, Inc. reported financial results for the first quarter ended March 31, 2026.","evidence_excerpt":"On May 12, 2026 , Opus Genetics, Inc., a Delaware corporation (the “Company”), issued a press release announcing its financial results for the first quarter ended March 31, 2026 .","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1228627/000162828026033856/0001628280-26-033856-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2026"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}